Hepatitis C treatment in drug users: Perception versus evidence

European Journal of Gastroenterology and Hepatology

Volumn 18, Issue 2, 2006, Pages 129-130

  Sylvestre, Diana ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BUPRENORPHINE; INTERFERON; METHADONE; PEGINTERFERON; RIBAVIRIN;

ADDICTION; CLINICAL TRIAL; DRUG USE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER INJURY; NONHUMAN; PERCEPTION; PRIORITY JOURNAL; REINFECTION; REVIEW;

ANTIVIRAL AGENTS; EVIDENCE-BASED MEDICINE; HEPATITIS C, CHRONIC; HUMANS; PATIENT COMPLIANCE; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT OUTCOME;

EID: 33644834065     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200602000-00003     Document Type: Review

References (19)

1. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
2. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Concales FL Jr., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
3. Heathcote J, Main J. Treatment of hepatitis C. J Viral Hepat 2005; 12:223-235.
4. Hrachovec J, Patel P. Weight-based ribavirin with pegylated interferon alfa 2b: benefits, risks, and the origin of the evidence. Gastroenterology 2003; 124:2003-2004; author reply 2004-2005.
5. Kim AI, Saab S. Treatment of hepatitis C. Am J Med 2005; 118:808-815.
6. Alter MJ, Moyer LA. The importance of preventing hepatitis C virus infection among injection drug users in the United States. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18 (Suppl. 1):S6-S10.
7. Sylvestre DL, Loftis JM, Hauser P, Genser S, Cesari H, Borek N, et al. Co-occurring hepatitis C, substance use, and psychiatric illness: treatment issues and developing integrated models of care. J Urban Health 2004; 81:719-734.
8. Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Soreson L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002; 136:288-292.
9. Robaeys G, Van Vlierberghe H, Matheï C, Van Ranst M, Bruckers L, Buntinx F. Eur J Gastroenterol Hepatol 2005; 18:159-166.
10. Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001; 34:188-193.
11. Van Thiel DH, Anantharaju A, Creech S. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. Am J Gastroenterol 2003; 98:2281-2288.
12. Mauss S, Berger F, Goelz J, Jacob B, Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004; 40:120-124.
13. Sylvestre DL, Litwin AH, Clements BJ, Gourevitch MN. The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. J Subst Abuse Treatment 2005; 29:159-165.
14. Dalgard O, Bjoro K, Hellum K, Myrvang B, Skaug K, Gutigard B, Bell H. Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. Eur Addict Res 2002; 8:45-49.
15. Backmund M, Meyer K, Edlin BR. Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin Infect Dis 2004; 39:1540-1543.
16. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001; 34:730-739.
17. Schiff ER. The alcoholic patient with hepatitis C virus infection. Am J Med 1999; 107:95S-99S.
18. McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 2000; 284:1689-1695.
19. Edlin BR. Prevention and treatment of hepatitis C in injection drug users. Hepatology 2002; 36 (5 Suppl. 1):S210-S219.